

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

Name:

Ward:

PATIENT:

Name:

NHI:

Atezolizumab

INITIATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- Patient has locally advanced or metastatic non-small cell lung cancer
- and
- Patient has not received prior funded treatment with an immune checkpoint inhibitor for NSCLC
- and
- For patients with non-squamous histology there is documentation confirming that the disease does not express activating mutations of EGFR, ROS-1 or ALK tyrosine kinase unless not possible to ascertain
- and
- Patient has an ECOG 0-2
- and
- Patient has documented disease progression following treatment with at least two cycles of platinum-based chemotherapy
- and
- Atezolizumab is to be used as monotherapy at a dose of 1200 mg every three weeks (or equivalent) for a maximum of 16 weeks
- and
- Baseline measurement of overall tumour burden is documented clinically and radiologically

CONTINUATION – non-small cell lung cancer second line monotherapy

Re-assessment required after 4 months

Prerequisites (tick boxes where appropriate)

- Prescribed by, or recommended by a medical oncologist, or in accordance with a protocol or guideline that has been endorsed by the Health NZ Hospital.

and

- Patient's disease has had a complete response to treatment
- or
- Patient's disease has had a partial response to treatment
- or
- Patient has stable disease
- and
- Response to treatment in target lesions has been determined by comparable radiologic assessment following the most recent treatment period
- and
- No evidence of disease progression
- and
- The treatment remains clinically appropriate and patient is benefitting from treatment
- and
- Atezolizumab to be used at a maximum dose of 1200 mg every three weeks (or equivalent)
- and
- Treatment with atezolizumab to cease after a total duration of 24 months from commencement (or equivalent of 35 cycles dosed every 3 weeks)

I confirm that the above details are correct:

Signed: Date:

Use this checklist to determine if a patient meets the restrictions for funding in the **hospital setting**. For more details, refer to [Section H](#) of the Pharmaceutical Schedule. For community funding, see the [Special Authority Criteria](#).

PRESCRIBER

PATIENT:

Name:

Name:

Ward:

NHI:

Atezolizumab - continued

INITIATION – unresectable hepatocellular carcinoma

Re-assessment required after 6 months

Prerequisites (tick boxes where appropriate)

Patient is currently on treatment with atezolizumab and met all remaining criteria prior to commencing treatment

or

Patient has locally advanced or metastatic, unresectable hepatocellular carcinoma

and

Patient has preserved liver function (Child-Pugh A)

and

Transarterial chemoembolisation (TACE) is unsuitable

and

Patient has not received prior systemic therapy for the treatment of hepatocellular carcinoma

or

Patient received funded lenvatinib before 1 March 2025

or

Patient has experienced treatment-limiting toxicity from treatment with lenvatinib

and

No disease progression since initiation of lenvatinib

and

Patient has an ECOG performance status of 0-2

and

To be given in combination with bevacizumab

CONTINUATION – unresectable hepatocellular carcinoma

Re-assessment required after 6 months

Prerequisites (tick box where appropriate)

No evidence of disease progression

I confirm that the above details are correct:

Signed: Date: